A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT02368665

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02368665
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02368665. Randomized; quadruple masking; primary purpose treatment. Start 2014-12 (actual); primary completion 2015-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy
Condition
Essential Hypertension
Intervention (Drug)
Amlodipine 5mg
Intervention (Drug)
Amlodipine 5mg, Candesartan cilexetil 16mg
Intervention (Drug)
Amlodipine 10mg, Candesartan cilexetil 16mg
Lead sponsor
HK inno.N Corporation (class: industry)

Record details

Record id
cardio:ct-nct02368665
Content hash
4bb314b9dd383656555b09fffb33235caab698a14cf5e9b2881441aab07f22f0